Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Cologne

Cologne, 50931, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

lymphocyte predominant Hodgkin´s lymphoma (histologically proven)
clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR > 50mm/h)
age 18 - 75
WHO performance status 0-3
normal organ function
written informed consent

Exclusion criteria

classical Hodgkin´s lymphoma
composite lymphoma
leucocytes < 3000/µl
thrombocytes < 100.000/µl

Treatment and study plan

Rituximab

Drug

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Registry information

Official study title

Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.

Important dates

Study start: 2006
Primary completion: 2007
First posted: Jun 30, 2006
Registry last updated: Aug 12, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed